Pub. Date : 2010 Nov 1
PMID : 20921456
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | PURPOSE: To evaluate the safety, maximum-tolerated dose, pharmacokinetics, and pharmacodynamics of vandetanib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor inhibitor, administered once daily during and after radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. | vandetanib | kinase insert domain receptor | Homo sapiens |